acquired
Stage
1
Investors
About
Akarna Therapeutics was a biopharmaceutical company developing novel small molecule therapeutics targeting inflammatory and fibrotic diseases, with its lead program focusing on a potential best-in-class FXR agonist for the treatment of non-alcoholic steatohepatitis (NASH).
Explore Akarna Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.